Nintedanib is currently being tested in a Phase 2 clinical trial for LAM, with the expectation of suppressed proliferation of LAM cells and LAM-associated lymphangiogenesis (ClinicalTrials.gov, Identifier: NCT03062943). The gene discussed is TSC1; the disease is lymphangioleiomyomatosis.